Mr. Dave Mason reports

HLS THERAPEUTICS REPORTS ANNUAL MEETING RESULTS

HLS Therapeutics Inc. has released voting results from its annual meeting of shareholders held in a virtual format on June 26, 2026.

A total of 17,355,806 common shares, or 55.49 per cent of the total common shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as follows.

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the company's auditor with 16,273,112 votes (93.76 per cent) cast for and 1,082,694 votes (6.24 per cent) withheld.

Shareholders also approved the long-term incentive plan for the company, with 16,802,842 votes (99.25 per cent) cast for and 121,015 votes (0.75 per cent) cast against.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting psychiatric disorders and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.